Fig. 6
The impact of Foxo3 expression on leukemia-free survival time of the AML patients. a Normal Karyotypic patients. b Non-Favorable patients. c non-M3 patients
Fig. 6 | BMC Cancer
The impact of Foxo3 expression on leukemia-free survival time of the AML patients. a Normal Karyotypic patients. b Non-Favorable patients. c non-M3 patients